PROSTOX Standard targets CFRT (37–45 fractions) and MHFRT (20–28 fractions), expanding a regimen-specific platform aimed at predicting late GU toxicity after EBRT in localized prostate cancer.

Abstract: Enabling radiation shielding technology is imperative for deep space exploration of spacecraft and crewed missions to the moon and Mars. Radiation from the sun's gamma rays and from high ...

Abstract: In order to investigate the effect of aero-thermal radiation on star sensor detection capability in near-space hypersonic flight platforms, this article proposes a star sensor simulation ...

E David Crawford interviews Jason Efstathiou about the PARTIQoL trial, a Phase III study comparing proton beam therapy to IMRT for localized prostate cancer. Dr. Efstathiou presents the study's design ...